

## DAFTAR PUSTAKA

1. Restrepo MI, Aliberti S, Dela Cruz CS, Amati F, Sotgiu G. Community-acquired pneumonia. *Lancet*. 2021;398: 906–19.
2. Azmi S, Aljunid SM, Maimaiti N, Ali AA, Muhammad Nur A, De Rosas-Valera M, et al. Assessing the burden of pneumonia using administrative data from malaysia, indonesia, and the philippines. *International Journal of Infectious Diseases*. 2016 (49): 87-93.
3. Dinkes Sumatra Barat. Riset Kesehatan Dasar Provinsi Sumatera Barat Tahun 2018. Laporan Riskesdas Nasional 2018. 2018.
4. Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, Barreto-Filho JA, et al. Diagnosis and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. *JAMA*. 2013;309(4):355-63.
5. Guo Q, Song WD, Li HY, Zhou YP, Li M, Chen XK, Liu H, Peng HL, Yu HQ, Chen X, Liu N, Lü ZD, Liang LH, Zhao QZ, Jiang M. Scored minor criteria for severe community-acquired pneumonia predicted better. *Respir Res*. 2019 Jan 31;20(1):22.
6. Madhu S, Augustine S, Kumar YSR, M Kauser M, Kumar SRV, Jayaraju BS. Comparative study of CURB-65, Pneumonia Severity Index and IDSA/ATS scoring systems in community acquired pneumonia in an Indian tertiary care setting. *International Journal of Advances in Medicine*. 2017 Jun;4(3):693-700
7. Li HY, Guo Q, Song WD, et al. Modified IDSA/ATS Minor Criteria for Severe Community-Acquired Pneumonia Best Predicted Mortality. *Medicine (Baltimore)*. 2017;96(3):e6015.
8. Shaddock EJ. How and when to use common biomarkers in community-acquired pneumonia. *Pneumonia*. 2016 Dec;8(17):1-7.
9. Karakioulaki M, Stolz D. Biomarkers in Pneumonia-Beyond Procalcitonin. *Int J Mol Sci*. 2019 Apr 24;20(8).

10. Puspitasari A, Mawari A. Review Article: Presepsin: New Biomaker to Evaluate Empirical Antibiotic Therapy Outcome in Septic Condition. *Folia Medica Indonesiana*. 2020; 56(148).
11. Klouche K, Cristol J.P, Devin J, Gilles V, Kuster N, Larcher R et al. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients. *Ann. Intensive Care*. 2016;6:59.
12. Siljan WW, Holter JC, Michelsen AE, Nymo SH, Lauritzen T, Oppen K, Husebye E, Ueland T, Mollnes TE, Aukrust P, Heggelund L. Inflammatory biomarkers are associated with aetiology and predict outcomes in community-acquired pneumonia: results of a 5-year follow-up cohort study. *ERJ Open Res*. 2019 Mar 11;5(1).
13. Ito A, Ishida T. Diagnostic markers for community-acquired pneumonia. *Ann Transl Med*. 2020 May;8(9):609.
14. Ham JY, Song KE. A Prospective Study of Presepsin as an Indicator of the Severity of Community-Acquired Pneumonia in Emergency Departments: Comparison with Pneumonia Severity Index and CURB-65 Scores. *Lab Med*. 2019;50(4):364-369.
15. Ugajin M, Matsuura Y, Matsuura K, Matsuura H. Impact of initial darah presepsin level for clinical outcome in hospitalized patients with pneumonia. *J Thorac Dis*. 2019;11(4):1387-1396.
16. Sharma R, Sandroock CE, Meehan J, Theriault N. Community-acquired bacterial pneumonia-changing epidemiology, resistance patterns, and newer antibiotics: spotlight on delafloxacin. *Clin Drug Investig*. 2020;40(10):947- 60
17. Dahlan Z, Setiati S, Alwi I, Sudaya AW, Simadibrata KM, Setyahadi B, et al. Pneumonia. *Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI*. Jakarta: Interna Publishing. 2014. hal. 1608–19.
18. Mackenzie G. The definition and classification of pneumonia. *Pneumonia*. 2016;8 (1):1–5.
19. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. Adults. *N Engl J Med*. 2015;373(5):415–27.

20. Takaki M, Nakama T, Ishida M, Morimoto H, Nagasaki Y, Shiramizu R, et al. High incidence of community-acquired pneumonia among rapidly aging population in japan: a prospective hospital-based surveillance. *Jpn. J. Infect. Dis.* 2014;67:1-7.
21. Konomura K, Nagai H, Akazawa M. Economic burden of community-acquired pneumonia among elderly patients: a Japanese perspective. *Pneumonia (Nathan)*. 2017;9:19.
22. Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. *Lancet Glob Health*. 2018;6(6):619–29.
23. Miyashita N, Matsushima T, Oka M, Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. *Intern Med*. 2006;45(7):419-28.
24. Akira Suzuki, Noel Macalalad. Etiology and Epidemiology of Community-acquired pneumonia in adults requiring hospital admission: a prospective study in rural central philippines. *International Journal of Infectious Diseases*. 2019(87):46–53.
25. Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. *Lancet*. 2021;(398):906–19.
26. Farida H. Community-acquired pneumonia in indonesia. tesis. Erasmus Universiteit Rotterdam; 2015.
27. Center for Disease Control and Prevention (CDC). National Center for Health Statistics. 2021.
28. Moldoveanu B, Otmishi P, Jani P, Walker J, Sarmiento X, Guardiola J, et al. Inflammatory mechanisms in the lung. *Journal of Inflammation Research*. 2009;2:1 – 12
29. Jain V, Vashisht R, Yilmaz G, et al. Pneumonia Pathology. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK526116/>

30. Thomas J, Pociute A, Kevalas R, Malinauskas M, Jankauskaite L. Blood biomarkers differentiating viral versus bacterial pneumonia aetiology: a literature review. *Ital J Pediatr.* 2020;46(1):4.
31. Acharya AK, Satapathy R. A Deep Learning Based Approach towards the automatic diagnosis of pneumonia from Chest Radio-Graph. *Biomed Pharmacol J.* 2020; 12(1).
32. Garg M, Prabhakar N, Gulati A, Agarwal R, Dhooria S. Spectrum of imaging findings in pulmonary infections. Part 2: Fungal, mycobacterial, and parasitic. *Pol J Radiol.* 2019;84:e214-e223.
33. Singh A, Sadia Tomo U, Dodiya MK, et al. Clinical, Microbiological, Serological and Radiological Profile of Patients With Mild-Moderate and Severe Allergic Bronchopulmonary Aspergillosis (ABPA). *Cureus.* 2023;15(9):e44662.
34. El-Radhi AS. Fever in Common Infectious Diseases. *Clinical Manual of Fever in Children.* 2019;85-140.
35. Abbas AK, Lichtman AH, Pillai S. Basic immunology : functions and disorders of the immune system 5<sup>th</sup> edition. Elsevier. 2016:27-53
36. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thoraks.* 2013;58(5):377-82.
37. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. 2019:45-67.
38. Chenevier-Gobeaux C, Borderie D, Weiss N, Mallet-Coste T, Claessens Y. Presepsin [sCD14-ST], an innate immune response marker in sepsis. *Clin Chim Acta.* 2015;450:97–103.
39. Zou Q, Wen W, Zhang X. Presepsin as a novel sepsis biomarker. *World J Emerg Med.* 2014;5:16–9.
40. Galliera E, Massaccesi L, de Vecchi E, Banfi G, Corsi Romanelli MM. Clinical application of presepsin as diagnostic biomarker of infection: Overview and updates. *Biochim Clin.* 2020;44(1):21-7.



41. Takahashi G, Hoshikawa K, Suzuki R, Sato K, Hoshi S, Yoshinao D, et al. Development of a newly immunoassay specific for mouse presepsin (sCD14-ST). *Sci Rep* [Internet]. 2022;12(1):1–10.
42. Arai Y, Mizugishi K, Nonomura K, Naitoh K, Takaori-Kondo A, Yamashita K. Phagocytosis by human monocytes is required for the secretion of presepsin. *J Infect Chemother* [Internet]. 2015 Aug;21(8):564–9.
43. Shirakawa K, Al. E. The new sepsis marker, sCD14-ST, induction mechanism in the rabbit sepsis models. *Crit Care*. 2010;14(2):19.
44. Chenevier-Gobeaux C, Bardet V, Poupet H, Poyart C, Borderie D, Claessens YE. Presepsin (sCD14-ST) secretion and kinetics by peripheral blood mononuclear cells and monocytic THP-1 cell line. *Ann Biol Clin (Paris)* [Internet]. 2016 Jan;74(1):93-7.
45. Tanimura S, Fujieda Y, Kono M, Shibata Y, Hisada R, Sugawara E, et al. Clinical significance of darah presepsin levels in patients with systemic lupus erythematosus. *Mod Rheumatol* [Internet]. 2018 Sep 3;28(5):865-71.
46. Ikegame A, Kondo A, Kitaguchi K, Sasa K, Miyoshi M. Presepsin production in monocyte/macrophage-mediated phagocytosis of neutrophil extracellular traps. *Sci Rep* [Internet]. 2022;12(1):1–13.
47. Kotera A, Sagishima K, Tashiro T, Niimori D, Kamohara H, Kinoshita Y. A validation of presepsin levels in kidney dysfunction patients: Four case reports. *J Intensive Care*. 2014;2(1):2–5.
48. Masson S, Caironi P, Fanizza C, Thomae R, Bernasconi R, Noto A, et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. *Intensive Care Med*. 2015 Jan;41(1):12-20.
49. Chenevier-Gobeaux C, Trabattoni E, Roelens M, Borderie D, Claessens Y. Presepsin (sCD14-ST) in emergency department: the need for adapted threshold values? *Clin Chim Acta*. 2014;427:34–36.
50. Behnes M, Bertsch T, Lepiorz D, Lang S, Trinkmann F, Brueckmann M, et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. *Crit Care* [Internet]. 2014 Oct 5;18(5):507.

51. Zaninotto M, Mion MM, Cosma C, Rinaldi D, Plebani M. Presepsin in risk stratification of SARS-CoV-2 patients. *Clin Chim Acta* [Internet]. 2020
52. Assal HH, Abdelrahman SM, Abdelbasset MA, Abdelaziz M, Sabry IM, Shaban MM. Presepsin as a Novel Biomarker in predicting In-hospital Mortality in Patients With COVID-19 Pneumonia. 2020;(January).
53. Shirakawa K, Naitou K, Hirose J, Takahashi T, Furusako S. Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. *Clin Chem Lab Med* [Internet]. 2011 May 1;49(5):937–9.
54. Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). *Clin Chim Acta* [Internet]. 2011 Nov;412(23–24):2157–61.
55. Novelli G, Morabito V, Ferretti G, Pugliese F, Ruberto F, Venuta F, et al. Pathfast presepsin assay for early diagnosis of bacterial infections in surgical patients: preliminary study. *Transpl Proc*. 2013;45:2750–3.
56. Qi Z, Yu H, Zhang J, Li C. Presepsin as a novel diagnostic biomarker for differentiating active pulmonary tuberculosis from bacterial community acquired pneumonia. *Clin Chim Acta*. 2018;478:152–6.
57. Titova E, Eyrikh A, Titova Z. The role of presepsin in the diagnosis and assessment of severity of sepsis and severe pneumonia. *Ter Arkh*. 2018;90:44–7.
58. Park J, Yoon JH, Ki HK, Ko JH, Moon HW. Performance of presepsin and procalcitonin predicting culture-proven bacterial infection and 28-day mortality: A cross sectional study. *Front Med*. 2022;9(August):1–9.
59. Calandra T, Cohen J. The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit. *Crit Care Med* [Internet]. 2005 Jul;33(7):1538–48.
60. Faix JD. Biomarkers of sepsis. *Crit Rev Clin Lab Sci* [Internet]. 2013 Jan 12;50(1):23–36.
61. Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern G V. Epidemiology and Outcome of Nosocomial and Community-Onset Bloodstream Infection. *J Clin Microbiol* [Internet]. 2003 Aug;41(8):3655–60.

62. Viridis A, Dell'agnello U, Taddei S. Impact of inflammation on vascular disease in hypertension,. *Maturitas*.. 2014;78(3):179–183.
63. Biyik I, Caglar FNT, Isiksacan N, Kocamaz N, Kasapoglu P, Gedikbasi A, et al. Serum Presepsin Levels Are Not Elevated in Patients with Controlled Hypertension. *Int J Hypertens* [Internet]. 2018;2018:1–5.
64. Giavarina D, Carta M. Determination of reference interval for presepsin, an early marker for sepsis. *Biochem Medica*. 2015;25(1):64–68.
65. Miyoshi M, Inoue Y, Nishioka M, Ikegame A, Nakao T, Kishi S, Doi T, Nagai K. Clinical evaluation of presepsin considering renal function. *PLoS One*. 2019 Sep 6;14(9).
66. Kobayashi S, Amano H, Terawaki H, Kawaguchi Y, Yokoo T. Prediction of presepsin concentrations through commensurate decline in kidney function in the elderly. *Clin Chim Acta*. 2020 Jan;500:1-9.
67. Wang W, He Q, Yuan J, et al. The significance of presepsin in chronic kidney disease with sepsis. *Research Square*; 2022.
68. Koizumi Y, Shimizu K, Shigeta M, Okuno T, Minamiguchi H, Kito K, Hodohara K, Yamagishi Y, Andoh A, Fujiyama Y, Mikamo H. Darah presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients. *BMC Infect Dis*. 2017 Jan 5;17(1):27.
69. Agnello L, Bivona G, Parisi E, Lucido GD, Iacona A, Ciaccio AM, Giglio RV, Ziino O, Ciaccio M. Presepsin and Midregional Proadrenomedullin in Pediatric Oncologic Patients with Febrile Neutropenia. *Lab Med*. 2020 Nov 2;51(6):585-591.
70. Apiratwarakul K, Srimookda N, Phungoen P, Ienghong K, Tiamkao S, Bhudhisawasdi V. Presepsin Levels in Emergency Patients with Bacterial and Viral Infection. *Open-Access Maced J Med Sci*. 2020; 8(A):20-23
71. Bamba Y, Moro H, Aoki N, et al. Increased presepsin levels are associated with the severity of fungal bloodstream infections. *PLoS One*. 2018;13(10).
72. Tsuchida T, Ie K, Okuse C, et al. Determining the factors affecting serum presepsin level and its diagnostic utility: A cross-sectional study. *J Infect Chemother*. 2021;27(4):585-591.

73. Ha EY, Park IR, Chung SM, et al. The Potential Role of Presepsin in Predicting Severe Infection in Patients with Diabetic Foot Ulcers. *J Clin Med*. 2024;13(8):2311.
74. Guo Q, Li H yan, Song W dong, Li M, Chen X ke, Liu H, et al. Updating cut-off values of severity scoring systems for community-acquired pneumonia to orchestrate more predictive accuracy. *Ann Med*. 2023;55(1).
75. Huang D, He D, Gong L, et al. Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia and type 2 diabetes mellitus. *Crit Care*. 2021;25(1):419. Published 2021 Dec 7. doi:10.1186/s13054-021-03841-w
76. Javier H. Ticona, Victoria M. Zaccone, and Isabel M. McFarlane, "Community-Acquired Pneumonia: A Focused Review." *American Journal of Medical Case Reports*, vol. 9, no. 1 (2021): 45-52. doi: 10.12691/ajmcr-9-1-12
77. Iwai-Saito K, Shobugawa Y, Aida J, Kondo K. Frailty is associated with susceptibility and severity of pneumonia in older adults (A JAGES multilevel cross-sectional study). *Sci Rep*. 2021;11(1):7966. Published 2021 Apr 12. doi:10.1038/s41598-021-86854-3
78. Barbagelata E, Cillóniz C, Dominedò C, Torres A, Nicolini A, Solidoro P. Gender differences in community-acquired pneumonia. *Minerva Med*. 2020;111(2):153-165. doi:10.23736/S0026-4806.20.06448-4
79. Corica B, Tartaglia F, D'Amico T, Romiti GF, Cangemi R. Sex and gender differences in community-acquired pneumonia. *Intern Emerg Med*. 2022;17(6):1575-1588. doi:10.1007/s11739-022-02999-7
80. Ferrer M, Traverso C, Cilloniz C, Gabarrus A, Ranzani OT, Polverino E, et al. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non ventilated patients. *PLoS ONE*. 2018; 13(1): e0191721.
81. Aliberti S, Bellelli G, Belotti M, et al. Delirium symptoms during hospitalization predict long-term mortality in patients with severe pneumonia. *Aging Clin Exp Res*. 2015;27(4):523-531. doi:10.1007/s40520-014-0297-9
82. Sligl WI, Marrie TJ. Severe community-acquired pneumonia. *Crit Care Clin*. 2013;29(3):563-601. doi:10.1016/j.ccc.2013.03.009



83. Sonkaya E, Eroglu SA, Kaynar H, Akgun M. Etiology and Prognostic Factors of Community-Acquired Pneumonia. *Haydarpasa Numune Med J.* 2022;62(3):257–263.
84. Liapikou A, Cillóniz C, Gabarrús A, et al. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia. *Eur Respir J.* 2016;48(1):257-261. doi:10.1183/13993003.00191-2016
85. Ito A, Ishida T, Tokumasu H, et al. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort. *BMC Pulm Med.* 2017;17(1):78. Published 2017 May 2. doi:10.1186/s12890-017-0424-4
86. Ruan S, Huang C, Chien J, Kuo L, Ku S, Kuo P, et al. PaO<sub>2</sub>/FiO<sub>2</sub> Ratio and Risk of Death Among Mechanically Ventilated Patients. *Am J Respir Crit Care Med* 2019;199:A1634
87. Shaaban LH, Ahmed Y. Hemogram values in community acquired pneumonia. *Egyptian Journal of Chest Diseases and Tuberculosis.* 2015; 6(3):617-623
88. Ullah AR, Masood A, Amin S, Ali I. Predictive factors and outcomes of severe community acquired pneumonia in patients with respiratory failure. *Pak J Med Sci.* 2022;38(4Part-II):1031-1037. doi:10.12669/pjms.38.4.5312
89. Irawan D, Irvan Medison, Dewi Wahyu Fitriana, Dessy Mizarti. Leukopenia as a Prognostic Factor in Severe Community-Acquired Pneumonia with Sepsis: A Case Report. *Bioscmed* [Internet]. 2024Oct.4 [cited 2025Mar.1];8(12):5749-61. Available from: <https://www.bioscmed.com/index.php/bsm/article/view/1149>
90. Cilloniz C, Torres A. Host-targeted approaches to sepsis due to community-acquired pneumonia. *EBioMedicine.* 2022;86:104335. doi:10.1016/j.ebiom.2022.104335
91. de Mangou A, Combe A, Coolen-Allou N, Miltgen G, Traversier N, Belmonte O, et al. (2022) Severe community-acquired pneumonia in Reunion Island: Epidemiological, clinical, and microbiological characteristics, 2016–2018. *PLoS ONE* 17(4): e0267184.

92. Aziz FF, Suryadinata H, Wahyudi K. Pola bakteri pasien rawat inap pneumonia komunitas dewasa Rumah Sakit Hasan Sadikin Bandung tahun 2018
93. Irawan R, Reviono, Harsini. Korelasi Kadar *Copeptin* dan Skor PSI dengan Waktu Terapi Sulih Antibiotik Intravena ke Oral dan Lama Rawat Pneumonia Komunitas. *J Respir Indo*. 2019; 39(1)
94. Perhimpunan Dokter Paru Indonesia. Pneumonia Komunitas. Jakarta: PDPI. 2022
95. Candel, F.J.; Salavert, M.; Basaras, M.; Borges, M.; Cantón, R.; Cercenado, E.; Cilloniz, C.; Estella, Á.; García-Lechuz, J.M.; Garnacho Montero, J.; et al. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review. *J. Clin.Med.*2023,12,6864.
96. Lee, K.-R.; Hong, D.-Y.; Paik, J.-H.; Jung, H.-M. Prognostic Value of Darah Presepsin and Pneumonia Severity Index in Patients with Community- Acquired Pneumonia in the Emergency Department. *Medicina* 2022, 58, 1504.
97. Ozkan S, Kahveci U, Hur I, Halici A. Prognostic importance of serum presepsin level in pneumonia focal sepsis and its relationship with other biomarkers and clinical severity scores. *Saudi Med J*, 2021;42(9):994-1001. doi:10.15537/smj.2021.42.9.20210163
98. Tsuchida T, Ie K, Okuse C, et al. Determining the factors affecting serum presepsin level and its diagnostic utility: A cross-sectional study. *J Infect Chemother*. 2021;27(4):585-591. doi:10.1016/j.jiac.2020.11.013
99. Nagiub MS, Arafa MA, Hussein AG, Abdallah MZ. Role of Presepsin in Predicting The Severity and Outcome of Community Acquired Pneumonia in Pediatrics. *Zagazig University Medical Journal*. 2020; 26(3).
100. Titova E.A., Reutskaya E.M., Eyrikh A.R. Presepsin as a marker of sepsis and severe pneumonia. *Russian Pulmonology*. 2017; 27 (3):

- 366–370 (in Russian). DOI: 10.18093/086901892017273366370
101. Najm, R. A., AL-dujaili, A. N. G., & Hashim, J. M. (2022). Presepsin level in children infected with community-acquired pneumonia. *International Journal of Health Sciences*, 6(S1), 4233–4244.

